We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Occult Blood Test Increases Colon Cancer Screenings

By LabMedica International staff writers
Posted on 13 Aug 2013
A new study suggests that noninvasive fecal immunochemical tests (FIT) might be more effective in prompting participation in potentially lifesaving colorectal cancer (CRC) screening than colonoscopy, a more expensive and invasive procedure.

Researchers at UT Southwestern (Dallas, TX, USA) and the University of California, San Diego (UCSD, USA) identified 5,970 uninsured (undeserving) patients who were not up to date with CRC screening. More...
Mean patient age was 59 years, and 64% of patients were women. The sample populations was classified as 41% white, 24% black, 29% Hispanic, and 7% other race/ethnicity. The patients were subsequently assigned randomly to three groups.

One group was assigned to FIT outreach, consisting of mailed invitation to use and return an enclosed no-cost FIT (1,593 patients). A second was assigned to colonoscopy outreach, consisting of mailed invitation to schedule a no-cost colonoscopy (479 patients). The third group was assigned to usual care, consisting of opportunistic primary care visit–based screening (3,898 patients). In addition, the FIT and colonoscopy outreach groups received telephone follow-up to promote test completion. The main outcome measures were screening participation in any CRC test within one year.

The results showed that screening participation was significantly higher for both FIT (40.7%) and colonoscopy outreach (24.6%) groups than for usual care (12.1%). On analysis, screening was higher higher for FIT than for colonoscopy outreach among whites, blacks, and Hispanics. Rates of CRC identification and advanced adenoma detection were 0.4% and 0.8% for FIT outreach, 0.4%, and 1.3% for colonoscopy outreach, and 0.2% and 0.4% for usual care, respectively. Eleven of 60 patients with abnormal FIT results did not complete colonoscopy. The study was published in the August 5, 2013, edition of JAMA Internal Medicine.

“The study suggests that the best approach to offering and delivering screening to underserved populations may be through FIT,” said senior author Celette Sugg Skinner, MD, associate director of population science and cancer control at the UT Southwestern Cancer Center. “Questions for the future are whether superior participation can be maintained in the FIT group (because the test must be repeated every year) and how adherence rates will impact overall screening effectiveness and cost.”

FIT is a quick and easy test that requires no special preparation that is used to detect small amounts of occult blood in a patient's stool sample. Completed tests are then mailed to a laboratory for analysis.

Related Links:

UT Southwestern
University of California, San Diego



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Serum Indices Control
Acusera Serum Indices Control
New
Gastrointestinal Panel
Xpert® GI Panel
New
Drug Testing Assays
Atellica DT 250 Analyzer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image Credit: Shutterstock

Blood Test Could Guide Drug Selection to Prevent Repeat Heart Attacks and Strokes

Secondary prevention after myocardial infarction or stroke relies on antiplatelet therapy, yet responses vary widely and both recurrent thrombosis and bleeding remain persistent risks. In the United Kingdom,... Read more

Molecular Diagnostics

view channel
Image: The Avantect Pancreatic Cancer Test combines epigenomic, genomic, and glycan biomarkers with machine learning to detect pancreatic cancer-associated signals in blood (Photo courtesy of ClearNote Health)

Multiomic Blood Test Supports Noninvasive Monitoring and Subtyping in Pancreatic Cancer

Pancreatic ductal adenocarcinoma remains difficult to detect early and monitor during treatment, particularly in patients with homologous recombination defects. Clinicians also have limited noninvasive... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Pathology

view channel
Image: A new study demonstrates that vascular features in colorectal tumors could serve as prognostic biomarkers of disease outcome. (Image Credit: iStock)

Tumor Blood Vessel Features May Help Predict Colorectal Cancer Survival

Colorectal cancer outcomes vary widely, and tumor biology remains a key determinant of prognosis. Because neoplasms depend on a vascular supply, differences in intratumoral vessels may influence survival.... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image Credit: Adobe Stock

Mayo Clinic and Thermo Fisher Launch Multi-Omics Venture to Identify Early Disease Signals

Many diseases begin developing years before symptoms emerge, making early detection difficult for healthcare systems and clinical laboratories. Linking molecular changes with longitudinal health data could... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.